메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Gene Solutions and Pangea Laboratory Establish Strategic…

IRVINE, Calif., Jan. 21, 2026 -- Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring. Under the agreement, Gene Solutions will provide SOPs, funding, and technical support from its CAP-accredited NGS laboratories in Singapore and Vietnam. Pangea Laboratory will overs
- 김갑성 기자
- 2026-01-21 09:00
Insilico Medicine and Hygtia Therapeutics Enter New Globa…

[ 메디채널 김갑성 기자 ] Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insilico is eligible to receive up to USD 66 million in upfront and milestone payments. Insilico will lead the IND submission and Phase 1 clinical trial of ISM8969, after which Hygtia Therapeutics will take responsibility for further clinical development, regulatory filings, and commerciali
- 김갑성 기자
- 2026-01-21 08:15
Nanoscope Secures Japan MHLW Sakigake and Orphan Dru…

Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases Enhances strong global regulatory momentum, including multiple FDA expedited programs and five EMA Orphan designations FDA, EMA and PMDA conditionally approve the MOGENRY™ brand name Strengthens global pre-commercialization readiness and reinforces leadership in optogenetic therapy DALLAS, Jan. 21, 2026 -- Nanoscope Therapeuti
- 김갑성 기자
- 2026-01-21 06:00
Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gain…

DEERFIELD, Ill., Jan. 21, 2026 -- Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met with enthusiastic adoption by surgical teams who value convenience, versatility, and clinical performance. Hemopatch Sealing Hemostat is a ready-to-use, absorbable collagen pad designed for tissue sealing and hemostasis.1 The new room temperature format eliminates the need for refrigeration, streamli
- 김갑성 기자
- 2026-01-21 03:00
Syngene International extends long-term research collabo…

BENGALURU, India, Jan. 21, 2026 -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progress
- 김갑성 기자
- 2026-01-21 01:55
Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers…

HOUSTON, Jan. 20, 2026 -- Sino Biological, Inc. is proud to announce the launch of its innovative SwiftFluo® TR-FRET Kinase Assay Kits, a ready-to-use, high-performance solution designed to accelerate kinase activity detection and high-throughput kinase inhibitor screening. Leveraging advanced Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology, these kits deliver exceptional sensitivity, low background, and robust reproducibility. This enables rapid, reliable, and scalable screening of kinase inhibitors, outperforming traditional methods such as radioactive a
- 김갑성 기자
- 2026-01-20 23:00
LakeShore Biopharma to Hold Extraordinary General Meeting…

BEIJING, Jan. 20, 2026 -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held on February 12, 2026 at 11 a.m. (Beijing time) at Unit 1301, Tower 1, China Central Place, No. 81 Jianguo Road, Chaoyang District, Beijing, Pe
- 김갑성 기자
- 2026-01-20 20:00
SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging So…

[ 메디채널 김갑성 기자 ] Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflows TAICHUNG, Jan. 20, 2026 -- SAG today announced LiquidMate O, its debut UHF RFID label and a category-defining advancement in pharmaceutical RFID and item-level traceability. Built on an innovative, patent-pending antenna architecture, LiquidMate O delivers reliable direct-on-vial RFID tagging for liquid-filled injectable medications, an application long considered one of the most technically challenging in RFID deployment. Ineffective tr
- 김갑성 기자
- 2026-01-20 20:00
Solidion Technology Awarded Its Third Grant From The U.S. Ar…

Grant Proceeds Will Accelerate Research Into Advanced Fiber-based Electronic Battery Systems DALLAS, Jan. 20, 2026 -- Solidion Technology Inc. ("Solidion" or the "Company") (Nasdaq: STI), an advanced battery technology solutions provider, was notified by the U.S. Department of War/Army STTR Program that it has been awarded a grant to develop an advanced fiber-based electronic battery system built on a coaxial carbon nanotube (CNT) yarn architecture. This marks the third grant Solidion has received in the last six months. The Company previously announc
- 김갑성 기자
- 2026-01-20 19:00
4DMedical Secures US$100+ Million Funding to Accelerate U.S.…

[ 메디채널 김갑성 기자 ] Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more LOS ANGELES and MELBOURNE, Australia, Jan. 20, 2026 -- 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading "CT:VQ™" product and significantly boost research
- 김갑성 기자
- 2026-01-20 19:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분